Deutsche Bank Maintains Buy Rating and $14 PT on Anthera Pharmaceuticals

A report from Deutsche Bank reiterates its Buy rating and $14 price target on Anthera Pharmaceuticals ANTH. The report states, “We hosted a client call w/ the principal investigator (PI) of VISTA-16, the ph3 trial of varespladib in acute coronary syndrome (ACS). The PI was cautiously optimistic on success. We view VISTA-16 as high-risk but like risk/reward into data in Q2:12 (20%-30% down & 5x-6x up).” ANTH closed yesterday at $5.43.